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years with acute and chronic leukemia. Majority of UCB recipients
were mismatched at 2 loci. UCB recipients were younger, weighed
less, more likely to have advanced leukemia and received a lower
dose of nucleated cells. Outcomes after matched BM, mismatched
BM and UCB transplantation were compared using Cox propor-
tional hazards regression to adjust for potentially confounding
factors. Hematopoietic recovery was slower after mismatched BM
and UCB transplants. Rates of acute graft-versus-host disease
(GVHD) were similar, but chronic GVHD was higher after UCB
transplants (RR 1.97, 95% CI 1.34-2.89, p0.001). Risks of relapse
were similar. Compared to matched BM transplants, treatment-
related mortality (RR 2.09, 95% CI 1.60-2.73, p0.0001), treat-
ment failure (RR 1.56, 95% CI 1.24-1.96, p0.002) and overall
mortality (RR 1.63, 95% CI 1.29-2.06, p0.0001) was higher after
UCB transplants. Rates of treatment-related mortality, treatment
failure and overall mortality were similar after mismatched BM and
UCB transplants. Though outcomes were better after matched
transplants, in a cohort where 69% of UCB transplants were
mismatched at 2 loci and had advanced leukemia at transplantation,
outcomes were comparable to that observed after 1-antigen mis-
matched BM transplantation. Utilization of UCB units mis-
matched at 2 loci will increase donor availability for older subjects.
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HLA MATCHING IN UNRELATED HEMATOPOIETIC CELL TRANSPLAN-
TATION
Petersdorf, E.W. Department of Medicine, University of Washington,
Fred Hutchinson Cancer Research Center.
Hematopoietic cell transplantation (HCT) from unrelated do-
nors is a curative modality for hematologic malignancies. The
success of unrelated donor HCT has closely paralleled discoveries
about the genes and function of the human leukocyte antigen
(HLA) system, the major histocompatibility complex (MHC) in
humans. Availability of robust typing methods and the continued
growth of registries of HLA-typed volunteer donors have allowed
the identiﬁcation of suitable donors for increasing numbers of
patients. The clinical results of unrelated donor HCT have greatly
improved as a consequence of more complete understanding of the
immunogenetic barriers that give rise to host-versus-graft (HVG)
and graft-versus-host (GVH) reactions. Data support a new model
for optimal HLA matching of unrelated donors in which quanti-
tative and qualitative measures of donor-recipient disparity are
considered, and where stage of disease at the time of transplanta-
tion may inﬂuence the impact of HLA disparity. New HLA match-
ing data demonstrate the importance of allele matching at HLA-A,
B, C, DRB and DQB1. Routine testing of prospective patients and
their best matched donors should include high resolution DNA
typing for HLA-A, B, C, DRB1 and DQB1. Finally, if a fully
matched donor is not available, then mismatching should be lim-
ited to one or two loci, with preference to allele rather than antigen
level mismatches.
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HLA FACTORS TO CONSIDER IN SELECTING CORD BLOOD UNITS
Baxter-Lowe, L.A. University of California, San Francisco.
For unrelated umbilical cord blood transplantation, most trans-
plant centers currently use cell dose and HLA matching as impor-
tant determinants for selecting units for transplant. Several studies
have demonstrated that HLA matching improves transplant out-
comes when typing is low resolution for HLA-A and -B and
variable levels of resolution for HLA-DRB1. Although HLA
matching improves outcomes, cord blood transplants can be suc-
cessful with only 3/6 or 4/6 HLAmatches. For the cord blood units
currently searched by the NMDP, at least one 4/6 HLA-matched
cord blood unit with at least 80  107 TNC is available for nearly
all patients. It is estimated that overall, approximately 80% of
patients will have at least one 5/6 HLA-matched donor. However,
for African Americans, only about 42% will have at least one 5/6
matched unit.
For bone marrow transplantation, it has been demonstrated that
low resolution typing of HLA-A, -B, and -DRB1 is inadequate to
identify some HLA disparities that are clinically signiﬁcant. HLA
disparity detected by performing high resolution HLA typing and
typing of additional HLA loci has been associated with adverse
outcomes. It is hypothesized that the fundamental mechanisms
underlying these bone marrow transplant observations are likely to
be applicable to cord blood transplantation. This hypothesis is
being tested by the NIH COBLT study, which has reported an
interim analysis of high resolution typing of 188 donor-recipient
pairs. For these recipients, high resolution HLA-DRB1 typing was
available during donor selection; approximately 1/3 of these pairs
had additional HLA-A and -B disparity detected by retrospective
high resolution typing. Additional HLA disparity was most fre-
quently observed in Hispanic (70%) and Asian (67%) recipients.
Eight of the 188 patients received units that were matched for only
2/6 high resolution HLA types. The clinical signiﬁcance of these
HLA disparities is under investigation. Until the relationship be-
tween HLA matching and transplant outcomes is well understood,
high resolution typing might be considered for selection of cord
blood units for transplantation. This may be particularly helpful
for patients that are at highest risk for multiple underlying HLA
disparities.
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UMBILICAL CORD BLOOD VERSUS MARROW: THE SEARCH PROCESS
Barker, J., Wagner, J.E. Blood and Marrow Transplant Program,
University of Minnesota, Minneapolis, MN.
Major efforts have been made to increase minority representation
and reduce the time of the donor search. Despite these efforts,
many patients in need of urgent transplant are not able to identify
a suitable donor in a timely fashion. Factors responsible for the
prolonged search of marrow donor programs include: 1) require-
ment for allele level matching, 2) donor availability and 3) donor
attrition. In contrast, UCB has the major advantage of rapid avail-
ability and relaxed level of HLA matching. Between 2000 and
2001, the median time to obtain an UCB graft was 13.5 days as
compared to 50 days for a volunteer BM donor at the University of
Minnesota. However, the identiﬁcation of an UCB donor is most
often limited by the availability of a unit with an adequate cell dose,
particularly for adults and older adolescents. While only 30% of
adults at the University of Minnesota were able to ﬁnd an ade-
quately dosed UCB graft in 2000-2001, the availability of double
unit UCB transplantation has virtually eliminated the obstacle of
cell dose. In 2002-2003, of 122 consecutive adult transplant refer-
rals who had a formal UCB search, using UCB unit selection
criteria of 4-6/6 HLA-A,B,DRB1 match, and combining 2 units for
patients with no single unit 3.5  107 NC/kg, a satisfactory graft
was identiﬁed for all patients. While major advances have been
made, additional obstacles have been identiﬁed impacting the UCB
search process: lack of a centralized search process and absence of
standardized procedures for qualifying cord blood banks. With
major advances in the search process for both adult and UCB
donors, the choice of stem cell source today is based on diagnosis,
degree of urgency, relative availability of adequately matched BM
versus UCB of adequate match and dose, institutional research
priority and physician preference.
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CORD BLOOD TRANSPLANTATION IN GENETIC DISORDERS
Kurtzberg, J. Duke University Medical Center, Durham, NC.
Cord blood stem and progenitor cells can rescue the bone mar-
row and immune system of pediatric and some adult patients
undergoing myeloablative chemotherapy. Cord blood cells exhibit
immunologic tolerance allowing transplantation across partially
mismatched HLA barriers increasing access to allogeneic trans-
plantation therapy for patients in need. Cord blood cells may also
be capable of transdifferentiation into non-hematopoietic tissues.
This property would make this stem cell source an ideal candidate
for future cellular therapies for tissue repair and regeneration. In
our center since 1995, banked, unrelated donor umbilical cord
blood has been used to transplant 100 infants and children with
inborn errors of metabolism. The results in these pediatric patients
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serve as a demonstration that cord blood cells can differentiate into
non-hematopoietic tissues.
All children were prepared for transplant with myeloablative
chemotherapy consisting of busulfan, cyclophosphamide and anti-
thymocyte globulin. Prophylaxis against GvHD was administered
with cyclosporine and methylprednisolone. Supportive care was
provided with IVIG, G-CSF, low dose heparin for VOD prophy-
laxis, leukocyte depleted and irradiated PRBC and platelet trans-
fusions, total parenteral nutrition, prophylactic antiviral and anti-
fungal antibiotics and empiric antibiotic therapy for fever. Thirty
ﬁve young children with Hurler syndrome (MPS I) were trans-
planted with partially HLA mismatched unrelated donor umbilical
cord blood over the past 8 years. All had the severe phenotype.
Neutrophil (ANC 500/	L) and platelet (50k/	L) engraftment
occurred in a median of 20 and 63 days respectively. Moderate to
severe acute GvHD occurred in 28 % of patients. Extensive
chronic GvHD was not seen. Twelve percent of patients had
serious events, graft rejection (n  1), infectious deaths (n  3),
toxic death (n 1, hyperammonemia). All other patients (87%) are
surviving event-free for a median greater than 3 years. All surviving
children remain full donor chimeras and have shown increasing
velocities of gains of neurocognitive functions. Skeletal growth
improved with only 4/11 children with severe kyphosis requiring
orthopedic surgery post transplantation therapy. No child devel-
oped clinical cardiac disease and corneal clouding improved in all.
Additional children (60) with lysosomal storage diseases includ-
ing metachromatic leukodystrophy, adrenoleukodystrophy and
globoid leukodystrophy (Krabbe disease) have been transplanted
with unrelated donor umbilical cord blood over the past 9 years. In
asymptomatic children, disease was arrested before the onset of
neurologic dysfunction. In symptomatic children disease progres-
sion was arrested within 6-9 months of the transplant procedure. In
a child with advanced Krabbe disease who died 1 year post trans-
plant, engraftment of donor cells was noted in the brain. Differ-
entiation to oligodendrocytes was demonstrated in vitro and sub-
sequently, in vivo. In a child with MPS III (Sanﬁlippo syndrome),
donor cells differentiated into cardiac myocytes in the heart 6
months post transplant.
These studies suggest that cord blood is capable of transdiffer-
entiation into non-hematopoietic lineages. Further studies are
needed to fully deﬁne the potential of these cells for cellular
therapies and tissue repair.
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UNRELATED DONOR CORD BLOOD TRANSPLANTATION FOR CHILDREN
WITH HEMATOLOGICAL MALIGNANCIES
Zecca, M., Locatelli, F. Pediatric Hematology, IRCCS Policlinico San
Matteo, Pavia, Italy.
Cord blood (CB) contains a large amount of hematopoietic
progenitors and over the last decade has been largely employed to
transplant children with either malignant or non-malignant disor-
ders. Advantages related to the use of CB cells are represented by
the low risk of acute and chronic graft-versus-host disease
(GVHD), prompt availability of this source of hematopoietic pro-
genitors, which shortens the time needed to locate a suitable
donor, and by the possibility of performing transplants in the
presence of 1 or 2 HLA disparities in the donor/recipient pairs.
Both these latter two factors can be relevant for treating children
with malignancies, whose disease, often running an aggressive
clinical course, might not allow an extended period of time for
ﬁnding a suitable unrelated bone marrow donor. Hundreds of
children with acute lymphoblastic or myeloid leukemia have re-
ceived an allograft of unrelated CB cells. The experience derived
from these patients has demonstrated that results achieved with
this type of transplant are substantially comparable to those ob-
tained in children given bone marrow transplantation. In particu-
lar, the risk of leukemia recurrence is not increased after CB
transplantation. Disease status at time of transplantation is the
main factor inﬂuencing patient’s outcome, patients transplanted in
1st-2nd remission being those with the best results. Both a higher
transplant-related mortality and an increased risk of leukemia re-
currence contribute to the worse outcome of patients given the
allograft in more advanced disease. As most deaths occurring in
children given CB transplantation are due to infectious complica-
tions (related to both delayed hematopoietic recovery and lack of
adoptive transfer of memory T-cells) strategies able to accelerate
both hematopoietic and immune reconstitution could widen the
use of CB cells for transplantation.
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THE ROLE OF CORD BLOOD TRANSPLANTATION IN THALASSEMIA
Walters, M. Oakland Children’s Hospital, Oakland, CA.
More than 20 years ago, the ﬁrst successful cure of 
-thalassemia
major by bone marrow transplantation was reported. Since then,
more than 1500 patients have been treated in this manner. In
Pesaro Italy where more than 1000 patients have received marrow
transplantation, the 20-year probability of thalassemia-free survival
is approximately 70%. Updated results strongly suggest that im-
proved outcomes across risk categories have occurred as effective
supportive care and conditioning regimen modiﬁcations have been
applied to this setting. As with other non-malignant conditions, the
alternative of increasingly effective supportive care also impacts
upon the decision to pursue transplantation, even when transplant
outcomes are very good. Umbilical cord blood (UCB) transplan-
tation, thus, must compare favorably to proven therapeutic alter-
natives before its use can be expanded. UCB is an attractive alter-
native to other stem cell sources due to its decreased incidence of
graft-versus-host disease (GVHD) and rapid tempo of immuno-
logical reconstitution after transplantation. Initial results of UCB
transplantation for thalassemia suggest that acceptable out-
comes are possible if measures are taken to mitigate the risk of
graft rejection. Among 44 patients with sickle cell disease or
thalassemia who received augmented conditioning therapy, the
event-free survival was 94% compared to 62% among those who
received a standard combination of busulfan and cyclophosph-
amide, with or without horse anti-thymocyte globulin. These
early results also support the importance of banking efforts to
expand the collection of related and unrelated UCB units. The
clinical experience of unrelated UCB transplantation for thalas-
semia remains very limited. New techniques to prevent GVHD
and promote engraftment, coupled with reﬁned donor selection
criteria should expand the availability of transplantation for
thalassemia major.
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RESULTS OF UNRELATED CORD BLOOD TRANSPLANT IN PATIENTS
WITH BONE MARROW FAILURE SYNDROMES
Gluckman, E. Eurocord, Hospital Saint Louis, Paris, France.
In Fanconi anemia (FA) patients without an HLA identical bone
marrow donor, search for an unrelated cord blood donor is an
option, however few results have been reported so far. In the
Eurocord registry, we have analyzed 44 patients with FA receiving
an unrelated cord blood transplant (UCBT). The median age was
7.7 years and median follow-up 20 months (8-83). At UCBT, the
median number of neutrophils was 620/mm3 and 13 patients had
received more than 20 red blood cell transfusions. The cord blood
was HLA mismatched in 37 patients (HLA-A and B by serology
and DRB1 high resolution typing, 5/6  21, 4/6  12 and 3/6 
3). The median number of nucleated cells (NC) at freezing was 5.5
 107/kg and at infusion 4.7  107/kg. Eighteen patients received
CY and irradiation based preparative regimens, 12 patients ﬂudara-
bine (FLU) containing regimen, 6 CY alone and 8 other regimens.
GVHD prophylaxis consisted of CSA and MTX (43%) or CsA
alone (23%). Results: Neutrophil recovery at day 60 was 56% 
8%. Two factors were associated with higher probability of neu-
trophil recovery (cell dose and number of HLA disparities). Acute
GVHD (II-IV) was 23%  6% (grade II  7%, III  7%, IV 
11%) and chronic GVHD occurred in 4/21 patients at risk (19%).
Two year survival was 36%  7%. In univariate analysis factors
associated with better survival were negative CMV serology,
NC at freezing or infused, higher neutrophil count at UCBT
and FLU containing regimen. In multivariate analysis only two
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